Litigation Details for NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)
✉ Email this page to a colleague
NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)
| Docket | ⤷ Sign Up | Date Filed | 2014-12-03 |
| Court | District Court, D. New Jersey | Date Terminated | 2015-12-02 |
| Cause | 35:271 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Patents | 8,324,189 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2014-12-02 | 1 | prior to the expiration of U.S. Patent No. 8,324,189 (“the ’189 patent”). … ’189 patent. A copy of the ’189 patent is attached as Exhibit A. The claims of the ’189 patent are valid… 2. This is an action for patent infringement under the patent laws of the United States, Title…concentrate. B. The Patent-In-Suit 13. The ’189 patent, entitled “Use of zolendronate…covered by certain claims of the ’189 patent. Accordingly, the ’189 patent is listed in connection with Zometa | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
